search
Back to results

A Clinical Trial of Extraperitonealization for Prevention of Parastomal Hernia After Ileal Conduit

Primary Purpose

Bladder Cancer

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Modified ileal conduit
Sponsored by
Sun Yat-sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Bladder Cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18-75 years old, gender not limited, life expectancy is greater than or equal to 24 months;
  2. ECOG score of patients: 0-1;
  3. Volunteer to participate in this study and sign the informed consent;
  4. T2-T4a, N0-x,M0 invasive bladder cancer; High risk non-muscular invasive bladder cancer T1G3(high grade) tumor; Tis in which BCG therapy failed; Recurrent non-invasive bladder cancer; TUR and bladder perfusion were used for treatment of uncontrolled extensive papillary lesions and bladder non-urothelial carcinoma;
  5. Major organ functions, such as liver, kidney, bone marrow, heart and other important organs, were not significantly abnormal: AST, ALT≤2.5 upper limit of normal value (ULN); Total bilirubin (TBIL)≤1.5 ULN; Albumin (ALB)≥25g/L; Serum creatinine (CRE)≤1.5 ULN; Leukocytes≥3.5*109/L, neutrophils≥1.5*109/L, hemoglobin≥90g/L, platelets≥80*109/L; Left ventricular ejection fraction (LVEF) ≥50%; Electrocardiogram showed no obvious abnormality or no clinical significance.

Exclusion Criteria:

  1. A history of major middle and lower abdominal surgery;
  2. Obese patients (BMI≥40kg/m2);
  3. Failure to receive regular follow-up review as required;
  4. Severe cardiovascular disease;
  5. History of immunodeficiency and organ transplantation;
  6. History of severe central nervous system disease

Sites / Locations

  • Cancer Center, Sun Yat-sen UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Modified ileal conduit

Conventional ileal conduit

Arm Description

With our modified ileal conduit technique

Conventional ileal conduit

Outcomes

Primary Outcome Measures

Incidence of parastomal hernia in 2 years
Incidence of parastomal hernia in 2 years

Secondary Outcome Measures

Incidence of stomal retraction in 2 years
Incidence of stomal retraction in 2 years
Incidence of stomal stenosis in 2 years
Incidence of stomal stenosis in 2 years
Incidence of stomal prolapse in 2 years
Incidence of stomal prolapse in 2 years
Overall Survival
Overall Survival
Disease-Free Survival
Disease-Free Survival

Full Information

First Posted
January 23, 2019
Last Updated
January 28, 2019
Sponsor
Sun Yat-sen University
search

1. Study Identification

Unique Protocol Identification Number
NCT03822234
Brief Title
A Clinical Trial of Extraperitonealization for Prevention of Parastomal Hernia After Ileal Conduit
Official Title
A Prospective Multicenter Randomized Controlled Clinical Trial of Extraperitonealization for Prevention of Parastomal Hernia After Ileal Conduit
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 15, 2019 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sun Yat-sen University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Many complications may occur after ileal conduit, with the incidence increasing with time after surgery. Nearly half of the complications are related to stoma and ureteroileal anastomosis. The investigators believe that the surgical technique is responsible for these complications, and therefore have devised a modified technique for creating the ileal conduit that should help prevent these complications after surgery. The investigators' retrospective study shows that modified surgical technique for ileal conduit urinary diversion appears to be effective for reducing early and late complications related to the stoma. Thus the investigators would like to perform a prospective multicenter randomized controlled clinical study to prove the investigators' results. The investigators plan to enroll 104 patients, and randomizedly divide the participants into two groups, with one group 52 patients undergoing conventional ileal conduit, another group 52 patients undergoing modified ileal conduit.
Detailed Description
The ileal conduit (Bricker) has been used for urinary diversion for more than half a century. Widely accepted to be a simple and safe form of urinary diversion, it remains one of the most commonly used techniques for urinary diversion after radical cystectomy for bladder cancer. However, many complications may occur after ileal conduit, with the incidence increasing with time after surgery. Interestingly, nearly half of the complications are related to stoma and ureteroileal anastomosis. Among the complications, parastomal hernia is the most common. Female gender, low preoperative serum albumin level, high BMI or severe obesity, and prior laparotomy have been shown to be risk factors for parastomal hernia. But the mechanisms by which these variables lead to stoma related complications have not yet been fully elucidated. The investigators believe that the surgical technique is responsible for these complications, and therefore have devised a modified technique for creating the ileal conduit that should help prevent these complications after surgery. The investigators' retrospective study shows that modified surgical technique for ileal conduit urinary diversion appears to be effective for reducing early and late complications related to the stoma. Thus the investigators would like to perform a prospective multicenter randomized controlled clinical study to prove the investigators' results. The investigators plan to enroll 104 patients, and randomizedly divide the participants into two groups, with one group 52 patients undergoing conventional ileal conduit, another group 52 patients undergoing modified ileal conduit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Cancer

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
104 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Modified ileal conduit
Arm Type
Experimental
Arm Description
With our modified ileal conduit technique
Arm Title
Conventional ileal conduit
Arm Type
No Intervention
Arm Description
Conventional ileal conduit
Intervention Type
Procedure
Intervention Name(s)
Modified ileal conduit
Intervention Description
Modified ileal conduit (Extraperitonealization)
Primary Outcome Measure Information:
Title
Incidence of parastomal hernia in 2 years
Description
Incidence of parastomal hernia in 2 years
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Incidence of stomal retraction in 2 years
Description
Incidence of stomal retraction in 2 years
Time Frame
2 years
Title
Incidence of stomal stenosis in 2 years
Description
Incidence of stomal stenosis in 2 years
Time Frame
2 years
Title
Incidence of stomal prolapse in 2 years
Description
Incidence of stomal prolapse in 2 years
Time Frame
2 years
Title
Overall Survival
Description
Overall Survival
Time Frame
up to 2 years. From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 24 months
Title
Disease-Free Survival
Description
Disease-Free Survival
Time Frame
up to 2 years. From date of randomization until the date of first documented progression or recurrence or date of death from any cause, whichever came first, assessed up to 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-75 years old, gender not limited, life expectancy is greater than or equal to 24 months; ECOG score of patients: 0-1; Volunteer to participate in this study and sign the informed consent; T2-T4a, N0-x,M0 invasive bladder cancer; High risk non-muscular invasive bladder cancer T1G3(high grade) tumor; Tis in which BCG therapy failed; Recurrent non-invasive bladder cancer; TUR and bladder perfusion were used for treatment of uncontrolled extensive papillary lesions and bladder non-urothelial carcinoma; Major organ functions, such as liver, kidney, bone marrow, heart and other important organs, were not significantly abnormal: AST, ALT≤2.5 upper limit of normal value (ULN); Total bilirubin (TBIL)≤1.5 ULN; Albumin (ALB)≥25g/L; Serum creatinine (CRE)≤1.5 ULN; Leukocytes≥3.5*109/L, neutrophils≥1.5*109/L, hemoglobin≥90g/L, platelets≥80*109/L; Left ventricular ejection fraction (LVEF) ≥50%; Electrocardiogram showed no obvious abnormality or no clinical significance. Exclusion Criteria: A history of major middle and lower abdominal surgery; Obese patients (BMI≥40kg/m2); Failure to receive regular follow-up review as required; Severe cardiovascular disease; History of immunodeficiency and organ transplantation; History of severe central nervous system disease
Facility Information:
Facility Name
Cancer Center, Sun Yat-sen University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fang-Jian Zhou, M.D Ph.D
Phone
+8613922735659
Email
zhoufj@sysucc.org.cn
First Name & Middle Initial & Last Name & Degree
Zhi-Ling Zhang, M.D Ph.D
Phone
+8613929527746
Email
zhangzhl@sysucc.org.cn
First Name & Middle Initial & Last Name & Degree
Fang-Jian Zhou, M.D Ph.D
First Name & Middle Initial & Last Name & Degree
Zhi-Ling Zhang, M.D Ph.D
First Name & Middle Initial & Last Name & Degree
Zhi-Yong Li, M.D Ph.D

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Clinical Trial of Extraperitonealization for Prevention of Parastomal Hernia After Ileal Conduit

We'll reach out to this number within 24 hrs